Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

BACKGROUND: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50% and no epidermal growth factor receptor (EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Loong, Herbert H., Wong, Carlos K. H., Leung, Linda Kam Suet, Dhankhar, Praveen, Insinga, Ralph P., Chandwani, Sheenu, Hsu, Danny C., Lee, Mary Y. K., Huang, Min, Pellissier, James, Rai, Akanksha, Achra, Monika, Tan, Seng Chuen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248157/
https://www.ncbi.nlm.nih.gov/pubmed/31531842
http://dx.doi.org/10.1007/s41669-019-00178-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248157/
https://www.ncbi.nlm.nih.gov/pubmed/31531842
http://dx.doi.org/10.1007/s41669-019-00178-7

Ejemplares similares